Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET

Company Participants

Dan Dischner - Vice President, Corporate Communications

Bill Peters - Chief Financial Officer

Dan Dischner - Vice President of Corporate Communications

Tony Marrs - Senior Vice President of Regulatory Affairs and Clinical Operations

Conference Call Participants

David Amsellem - Piper Sandler

Serge Belanger - Needham & Company

Elliot Wilbur - Raymond James

Operator

Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]

Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Forward-Looking Statements in the press release issued today and the presentation on the Company's website.

Also, please refer to our SEC filings, which can be found on our website and the SEC website, for a discussion of numerous factors that may impact our future performance. We will also discuss certain non-GAAP measures. Important information on the use of these measures and reconciliations to U.S. GAAP may be found in our earnings release. Please note that this conference call is being recorded.

Our speakers today are Mr. Bill Peters, CFO; Mr. Dan Dischner, Vice President of Corporate Communications; and Mr. Tony Marrs, Senior Vice President of Regulatory Affairs and Clinical Operations.

I will now turn the conference over to your host, Mr. Dan Dischner, Vice President of Corporate Communications. Dan, you may begin.

Dan Dischner

Thank you, Paul. And I'd like to thank everyone for joining us today. On the call with me will be Bill Peters, CFO and Executive Vice President of Finance; and Tony Marrs, Senior Vice President of Regulatory Affairs and Clinical Operations. Following my remarks and Bill's financial update, we'll open up for Q&A with the management team.

I want to start by highlighting our third quarter's financials at a high level and then provide some remarks regarding our products and our pipeline with further discussion on glucagon's evolving market dynamics. We remain encouraged by our progress with net revenues of $120.1 million, up 7% from the same period last year.

Our balance sheet is stronger than ever and provides us the flexibility to continue investing in our robust pipeline. Therefore, R&D investments, as seen in the third quarter, continue to be a priority for us as we remain committed to advancing our pipeline toward approval and launch of special regard to our inhalation, internasal and insulin products.